We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Cellectricon Launches Dynaflow™ Pro II System

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

Cellectricon has announced the launch of the Dynaflow™ Pro II System for safety pharmacology studies. 

The system comes with the DF-8 Pro II Chip beta-tested for conducting GLP hERG studies by Swiss ion channel CRO bSys GmbH.

Developed for life scientists and drug discovery researchers, the Dynaflow System is an add-on to conventional patch-clamp and provides a solution to the current need for increased throughput and data quality in ion channel drug discovery.

The system now comes with the Dynaflow 8-channel microfluidic chip (DF-8 Pro II Chip) designed for cumulative dose-response work and/or screening of slow acting compounds on non-desensitizing ion channels.

The DF-8 Pro II Chip has been beta-tested by the Swiss ion channel CRO bSys GmbH, who studied a variety of hERG inhibitory substances with results demonstrating the system performance as ideally suited for safety pharmacology studies.

Dr. Med. Daniel Konrad, CEO of bSys GmbH, said, "We have incorporated the Dynaflow system and the new DF-8 Pro II Chip into our cardiac safety assessment services."

"The system enabled us to perform standardized and reproducible GLP hERG studies of ion channels with outstanding data quality."

"We've developed the new DF-8 Pro II Chip and Dynaflow Pro II Platform to meet the increasing demand for a system with safety pharmacology performance," stated Mattias Karlsson, Ph.D., VP R&D at Cellectricon.

"With the new Dynaflow Pro II System, and Dynaflow Microfluidic Chips (8-, 16- and 48-channels), Cellectricon now offers a complete product range for ion channel drug discovery."